Windsor Private Capital Lp Sells 19,222 Shares of Firefly Neuroscience (NASDAQ:AIFF) Stock

Firefly Neuroscience, Inc. (NASDAQ:AIFF) major shareholder Windsor Private Capital Lp sold 19,222 shares of the company’s stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $2.40, for a total value of $46,132.80. Following the completion of the transaction, the insider owned 1,314,804 shares in the company, valued at $3,155,529.60. This represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Windsor Private Capital Lp also recently made the following trade(s):

• On Wednesday, October 22nd, Windsor Private Capital Lp sold 78,031 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.07, for a total value of $161,524.17.
• On Monday, October 20th, Windsor Private Capital Lp sold 33,500 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.46, for a total value of $82,410.00.
• On Friday, October 17th, Windsor Private Capital Lp sold 45,036 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.55, for a total value of $114,841.80.
• On Thursday, October 16th, Windsor Private Capital Lp sold 40,139 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.65, for a total value of $106,368.35.
• On Wednesday, October 15th, Windsor Private Capital Lp sold 17,500 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.74, for a total value of $47,950.00.
• On Tuesday, October 14th, Windsor Private Capital Lp sold 29,500 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.74, for a total value of $80,830.00.
• On Monday, October 13th, Windsor Private Capital Lp sold 32,136 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.65, for a total value of $85,160.40.
• On Friday, October 10th, Windsor Private Capital Lp sold 74,810 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.70, for a total value of $201,987.00.
• On Thursday, October 9th, Windsor Private Capital Lp sold 30,126 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.94, for a total value of $88,570.44.

Firefly Neuroscience Trading Up 1.0%

AIFF opened at $2.05 on Friday. The stock has a 50-day moving average price of $2.73 and a 200-day moving average price of $2.94. Firefly Neuroscience, Inc. has a 12-month low of $1.86 and a 12-month high of $17.20. The stock has a market capitalization of $27.57 million, a P/E ratio of -0.82 and a beta of 2.11.

Firefly Neuroscience (NASDAQ:AIFF) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter. Firefly Neuroscience had a negative return on equity of 464.02% and a negative net margin of 5,335.75%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Firefly Neuroscience in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Firefly Neuroscience presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Firefly Neuroscience

An institutional investor recently raised its position in Firefly Neuroscience stock. Geode Capital Management LLC boosted its stake in shares of Firefly Neuroscience, Inc. (NASDAQ:AIFF) by 92.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 120,604 shares of the company’s stock after acquiring an additional 58,067 shares during the quarter. Geode Capital Management LLC owned 0.94% of Firefly Neuroscience worth $341,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 4.96% of the company’s stock.

Firefly Neuroscience Company Profile

Firefly Neuroscience, Inc, a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder.